Online inquiry

IVTScrip™ mRNA-Anti-FCGRT, HL161(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8188MR)

This product GTTS-WQ8188MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets FCGRT gene. The antibody can be applied in Autoimmune diseases research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FCGRT, HL161(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ8188MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12470MR IVTScrip™ mRNA-Anti-IL20, NN-8226(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA NN-8226
GTTS-WQ8299MR IVTScrip™ mRNA-Anti-GLP1R, HM-12525A(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA HM-12525A
GTTS-WQ8939MR IVTScrip™ mRNA-Anti-IL1RL2, IL2 fused to diphteria toxin(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IL2 fused to diphteria toxin
GTTS-WQ7812MR IVTScrip™ mRNA-Anti-GLP1R, GSK 716155(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GSK 716155
GTTS-WQ10501MR IVTScrip™ mRNA-Anti-APP, LY3002813(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA LY3002813
GTTS-WQ2939MR IVTScrip™ mRNA-Anti-PDCD1, ANB-011(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ANB-011
GTTS-WQ5952MR IVTScrip™ mRNA-Anti-IGHE, CL-2C(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CL-2C
GTTS-WQ6108MR IVTScrip™ mRNA-Anti-IL6, COR-001(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA COR-001
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW